Claerhout Ilse, Beele Hilde, Van den Abeele Kathleen, Kestelyn Philippe
Department of Ophthalmology, Ghent University Hospital, Belgium.
Cornea. 2002 Oct;21(7):637-42. doi: 10.1097/00003226-200210000-00001.
To identify the influence of the underlying etiology on the outcome of therapeutic penetrating keratoplasty (PKP) in the management of corneal perforation, impending perforation or refractory corneal disease.
A retrospective observational case series with 28 patients (28 eyes) was performed. Patients were divided in two subgroups, based on the underlying ocular disease leading to the therapeutic PKP. Group I consisted of 15 patients (54%) with an infectious etiology, the other 13 patients (46%) with a noninfectious condition belonged to group II. Mean follow up was 23.2 months (median 21 months).
An enucleation could be avoided in all but two cases. In group I, 12 of 15 (80%) grafts remained clear, compared with only 3 of 13 (23%) in group II (p = 0.0004). Visual acuity (VA) amelioration was achieved in 20 of 28 patients (71%). In group I the postoperative VA was significantly better than preoperatively (p = 0.002); however, in group II the improvement was only borderline significant (p = 0.05). Overall five out of ten (50%) patients with a therapeutic PKP in group I had an endothelial cell density >or= 1900 cells/mm2 at the time of their last specular microscopy.
Our study demonstrates the importance of underlying etiology on the outcome of therapeutic PKP. Graft survival and postoperative visual acuity varied widely depending on the underlying ocular disease, and it was clear that therapeutic PKP has a much better prognosis in infectious conditions when compared with noninfectious conditions. We believe that these good results can justify the use of therapeutic PKP in selected cases of infectious keratitis.
确定潜在病因对治疗性穿透性角膜移植术(PKP)治疗角膜穿孔、即将穿孔或难治性角膜疾病疗效的影响。
进行一项回顾性观察性病例系列研究,纳入28例患者(28只眼)。根据导致治疗性PKP的潜在眼部疾病,将患者分为两个亚组。第一组由15例(54%)有感染性病因的患者组成,另外13例(46%)有非感染性疾病的患者属于第二组。平均随访时间为23.2个月(中位数21个月)。
除两例外,所有病例均避免了眼球摘除。在第一组中,15只移植眼中有12只(80%)保持透明,而在第二组中,13只移植眼中只有3只(23%)保持透明(p = 0.0004)。28例患者中有20例(71%)视力得到改善。在第一组中,术后视力明显优于术前(p = 0.002);然而,在第二组中,改善仅接近显著水平(p = 0.05)。总体而言,第一组中接受治疗性PKP的10例患者中有5例(50%)在最后一次角膜内皮镜检查时角膜内皮细胞密度≥1900个细胞/mm²。
我们的研究证明了潜在病因对治疗性PKP疗效的重要性。移植片存活率和术后视力因潜在眼部疾病的不同而有很大差异,显然与非感染性疾病相比,治疗性PKP在感染性疾病中的预后要好得多。我们认为,这些良好结果可为在某些感染性角膜炎病例中使用治疗性PKP提供依据。